ERG and prostate carcinoma: Recurrent gene fusions were primarily identified in prostate cancer (TMPRSS2::ERG) and adenoid cystic carcinoma (MYB::NFIB) in 1.74% (9/517) and 1.35% (7/517), respectively in the overall cohort.